BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Sequitur, Inc. (Acquired By Invitrogen) 

14 Tech Circle

Natick  Massachusetts  01760  U.S.A.
Phone: 508-650-1459 Fax: 508-655-1625


SEARCH JOBS
Sequitur, Inc. was founded in 1996 to develop innovative sequence-based compounds for functional genomics research, diagnostic, and therapeutic applications. Sequitur's proprietary antisense technology can be employed to determine gene function and validate small molecule targets by specifically inhibiting gene expression. We also offer a line of products and services relating to gene expression and gene detection. Research is performed in our recently renovated state-of-the-art GLP cellular and molecular biology laboratory space in Natick, Massachusetts. Sequitur's scientific advisory board includes leaders in the fields of oligonucleotide and gene therapy research. Sequitur provides services in the following interrelated areas:

ANTISENSE FUNCTIONAL GENOMICS PROGRAM
Based upon a yearly licensing fee, a corporate client obtains non-exclusive research use of Sequitur's current and newly developed functional genomics technology. Sequitur has one issued patent and five patents pending in the field of oligonucleotide technology. Research agreements are also available for Sequitur to experimentally determine optimal antisense sites within target genes.

HIGH THROUGHPUT ONE STEP TARGET DISCOVERY AND VALIDATION
Omniscreen™ is a modification of the current method of discovering and validating targets. The current method is restricted to identification of genes upregulated in disease states and requires years of research. This old method is replaced by Omniscreen ™ which applies a library of antisense oligos to targets using high throughput cell culture disease model screens.

Last Updated 7-24-01


 Key Statistics


Email: support@SequiturInc.com
Ownership: Subsidiary

Web Site: Sequitur, Inc. (Acquired By Invitrogen)
Employees: 20
Symbol: 
 



Industry
Biotechnology






 Company News
Invitrogen Corporation (IVGN) Acquires Sequitur, Inc. 10/19/2005 5:10:15 PM    More...

//-->